Analysts Name Top Biotech Stocks for 2010: BioBuzz
"Looking to 2010, we think that M&A activity for small and mid-cap cap biotech may pick up, driven by Pharma but also driven by large cap biotechs. In this report, we've stressed pipelines and sustainability of growth, but as growth in the large cap group matures, increased cash flow generation may fuel increased M&A activity."
Meacham and his team see the following companies in its U.S. coverage universe as having "high strategic value" in 2010: Acorda Therapeutics (ACOR), AMAG Pharmaceuticals (AMAG), OSI Pharmaceuticals (OSIP), Medivation (MDVN), United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), Human Genome Sciences (HGSI), Seattle Genetics (SGEN) and Savient Pharmaceuticals (SVNT)."
Meacham on new biotech IPOs in 2010:
"Looking ahead to 2010, we think the IPO window in biotech is likely to open again for several reasons: First, the healthcare reform overhang should be lifted, which should drive fund flows back into healthcare and biotech. Second, the economy has stabilized to a point where there is an increased appetite for risk, especially as the early cyclical trade draws to a close."Third, there is demand for new stories in biotech. We have consistently heard that a lot of the names in biotech are too 'picked over,' and investors are hungry for new ideas. Fourth, there are a lot of interesting, high-quality, later-stage IPO stories that are likely to attract significant investor attention." Geoff Porges of Sanford Bernstein on the four reasons why he likes the big-cap biotech group despite last year's dismal performance: "First, operating performance is likely to continue to be solid, with some modest upside, in the first part of 2010. Guidance is likely to still be cautious, but may be marginally more encouraging than in 2009 when demand appeared to be stalling for certain products. Second, important late stage pipeline assets are reaching pivotal regulatory and commercial milestones and could drive a reversal of negative sentiment about the group as they come to market in the next 18 months.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV